Yeah...I think we all know the Phase II results are going to be nothing less than spectacular. The Chinese partner is where the kicker lies as that funding and marketing connection will put them over the edge to long-term growth potential in both the US and overseas. Note that this technology can be expanded to any disease, and not just Park./Alz./BreastCancer/etc...proteins and metabolites are where the real disease-related "information" lies, so expect metabolomics to follow shortly in this field of "omics" technologies. First was genomics, then proteomics, next is metabolomics (I work in nutritional and pharmacological metabolomics; trust me here).
Market Data 
Markets 
AI
